



LEIDEN UNIVERSITY TO STUDY IMMUNOVIA'S PANCREASURE TEST IN GROUP AT UNUSUALLY HIGH RISK FOR PANCREATIC CANCER

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced a new clinical validation study in partnership with Leiden University Medical Center. The study will evaluate the accuracy of Immunovia's next-generation blood test, PancreaSure, in individuals carrying the genetic mutation CDKN2A, a genetic profile associated with a lifetime pancreatic risk of 15–20%.

The case-control study will evaluate the accuracy of the Immunovia test in detecting Stage 1 and 2 pancreatic cancer in blood samples collected from approximately 150 CDKN2A patients in Leiden, home to a disproportionately high number of people who carry the mutation.

Leiden University Medical Center (LUMC) operates an extensive pancreatic cancer surveillance and research program for CDKN2A mutation carriers, seeing more than 300 patients annually. LUMC has collected blood samples from these patients for several years, creating an incredibly unique and valuable biobank for research.

"Individuals with the CDKN2A mutation face a terribly high risk of pancreatic cancer. We must improve early detection for these patients," said Prof. Monique van Leerdam, Professor of Gastroenterology and Hepatology at Leiden University Medical Center. "The CLARITI and VERIFI studies demonstrated that the PancreaSure test is highly accurate in detecting Stage 1 and 2 pancreatic cancer in high-risk individuals. We are eager to evaluate the test's performance in our CDKN2A patients."

"The Leiden group is world renowned for its research in pancreatic cancer, particularly in those with CDKN2A mutations," said Jeff Borcharding, Immunovia CEO. "We are honored Prof. van Leerdam and her team chose PancreaSure. This study is a significant opportunity to expand our clinical evidence to support reimbursement and regulatory submissions."

Immunovia is preparing for a commercial launch of the PancreaSure test in the U.S. market in September 2025. The company will conduct additional studies to assess the test's clinical impact and further evaluate its accuracy in other high-risk populations to support regulatory submissions and payer reimbursement efforts. Immunovia is also engaging potential commercial partners to accelerate market adoption.

For further information, please contact

Jeff Borcharding, CEO

jeff.borcharding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.

For more information, please visit www.immunovia.com.